ArticleBMC geriatrics2026
Feasibility of the tailored activity program to bridge hospital and community care for people living with dementia and behavioral disorders: The "Continu-A-Mente" project.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Tailored Activity Program (TAP) effectively manages Behavioral and Psychological Symptoms of Dementia (BPSD), yet its feasibility across the hospital-to-home care continuum for people living with dementia (PLwD) has not been tested.
objectiveTo assess the feasibility of TAP-Continu-A-Mente intervention for managing BPSD in PLwD transitioning from hospital to home, either following a short-stay observation or a memory clinic evaluation. Secondary aims were to evaluate changes in PLwD BPSD, caregiver distress and sense of competence, healthcare use, dyad satisfaction.
methodsThis single-arm interventional feasibility study enrolled 50 dyads (PLwD and caregivers) at IRCCS San Gerardo Hospital (Monza, Italy). PLwD inclusion criteria were age ≥65, dementia diagnosis, Neuropsychiatric Inventory (NPI) ≥6 in at least one item, independence in at least two basic activities of daily living, fluency in Italian. The intervention consisted of eight sessions over three months (two in hospital and six at home) delivered by occupational therapists. The primary outcome was the proportion of dyads completing the program (dyad retention). Secondary outcomes, assessed at baseline and four months, included NPI, Clinical Frailty Scale (CFS), motor-functional status (Katz Index, TUG), caregiver self-efficacy (SCQ), and dyad satisfaction.
resultsPLwD had a median age of 81 (Q1–Q3: 77–86), and 52% were female. Patient baseline median CFS was 6 (Q1–Q3: 6–7), and 78% received ≥12 hours/day of caregiver assistance. Caregivers were mostly female (76%) with a median age of 59 (Q1–Q3: 55.5–74). Dyad retention was 84% (42/50), with dropouts mainly older females. Among completers, NPI total scores decreased at follow-up (frequency x severity 42.5 vs 20.5, and caregiver distress 21 vs 14; p < 0.001), while SCQ score increased (52 vs 65; p < 0.001). CNS-active medication use increased overall, from 1 to 2. Katz Index declined from 4 to 3, whereas TUG remained stable (15.5 vs 16.3). No institutionalizations occurred, and one hospitalization was recorded. More than half of patients and caregivers rated their experience as 5/5.
conclusionsTAP-Continu-A-Mente was a feasible hospital-to-home model of care for PLwD with BPSD. The observed reductions in NPI scores should be considered hypothesis-generating, warranting further investigation.
trial registrationThe study protocol was approved by the Ethics Committee “Comitato Etico Brianza” (approval no. 4173, 12.01.2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.